RNPA1000

• CAT Number: I003316
• CAS Number: 359600-10-5
• Molecular Formula: C23H18BrN3O3
• Molecular Weight: 464.31
• Purity: ≥95%
• Target: Antibiotic
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 4-[3-[(E)-3-(3-bromoanilino)-2-cyano-3-oxoprop-1-enyl]-2,5-dimethylpyrrol-1-yl]benzoic acid
• InChI: InChI=1S/C23H18BrN3O3/c1-14-10-17(15(2)27(14)21-8-6-16(7-9-21)23(29)30)11-18(13-25)22(28)26-20-5-3-4-19(24)12-20/h3-12H,1-2H3,(H,26,28)(H,29,30)/b18-11+
• InChIKey: WQCMDUBFZYCGMI-WOJGMQOQSA-N
• SMILES: CC1=CC(=C(N1C2=CC=C(C=C2)C(=O)O)C)/C=C(\C#N)/C(=O)NC3=CC(=CC=C3)Br

RNPA1000（Cat No.:I003316）is a high-purity RNA polymerase inhibitor with potent activity against Gram-positive bacterial pathogens. It specifically targets bacterial RNA polymerase (RNAP), disrupting transcription and halting bacterial growth. RNPA1000 is widely studied for its potential to combat antibiotic-resistant infections, offering a novel mechanism of action distinct from traditional antibiotics. Its efficacy against clinically relevant pathogens makes it a valuable tool in antimicrobial research and drug development. This compound is instrumental in exploring transcriptional regulation, bacterial physiology, and innovative strategies for addressing the global challenge of antibiotic resistance.

Reference

[1]. Eidem TM, et al. Drug-eluting cements for hard tissue repair: a comparative study using vancomycin and RNPA1000 to inhibit growth of Staphylococcus aureus. J Biomater Appl. 2014 Apr;28(8):1235-46.
[2]. Eidem TM, et al. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28.